Identification

Name
Rimiducid
Accession Number
DB04974
Type
Small Molecule
Groups
Investigational
Description

Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade.1,6 The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.

Structure
Thumb
Synonyms
  • Rimiducid
External IDs
AP 1903 / AP-1903 / AP1903
Categories
UNII
H564L1W5J2
CAS number
195514-63-7
Weight
Average: 1411.65
Monoisotopic: 1410.677441572
Chemical Formula
C78H98N4O20
InChI Key
GQLCLPLEEOUJQC-ZTQDTCGGSA-N
InChI
InChI=1S/C78H98N4O20/c1-13-57(53-43-67(93-7)73(97-11)68(44-53)94-8)75(85)81-37-17-15-25-59(81)77(87)101-61(31-27-49-29-33-63(89-3)65(39-49)91-5)51-21-19-23-55(41-51)99-47-71(83)79-35-36-80-72(84)48-100-56-24-20-22-52(42-56)62(32-28-50-30-34-64(90-4)66(40-50)92-6)102-78(88)60-26-16-18-38-82(60)76(86)58(14-2)54-45-69(95-9)74(98-12)70(46-54)96-10/h19-24,29-30,33-34,39-46,57-62H,13-18,25-28,31-32,35-38,47-48H2,1-12H3,(H,79,83)(H,80,84)/t57-,58-,59-,60-,61+,62+/m0/s1
IUPAC Name
(1R)-3-(3,4-dimethoxyphenyl)-1-[3-({[2-(2-{3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyloxy]propyl]phenoxy}acetamido)ethyl]carbamoyl}methoxy)phenyl]propyl (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate
SMILES
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC1=CC=C(OC)C(OC)=C1)C1=CC(OCC(=O)NCCNC(=O)COC2=CC=CC(=C2)[C@@H](CCC2=CC=C(OC)C(OC)=C2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1)C1=CC(OC)=C(OC)C(OC)=C1

Pharmacology

Indication

Investigated for use/treatment in bone marrow transplant and graft versus host disease.

Pharmacodynamics

Rimiducis is used to activate inducible caspase-9 produced by a modified gene included in some CAR T-cell therapies.2,3 This activation produces rapid induction of apoptosis in activated modified T-cells and resolution of the signs and symptoms of graft versus host disease within 24 hours.4

Mechanism of action

Rimiducid binds to a drug binding domain derived from human FK506-binding protein which is present on a modified form of inducible caspase-9.2 This binding results in dimerization and subsequent activation of caspase-9. This system was designed to function as a "safety switch" in CAR T-cell therapy used in hematological cancers. Retroviral vectors used in production of these modified cells preferentially integrate this gene nearby promoters associated with T-cell activation. This results in higher expression of the modified inducible caspase-9 product in activated T-cells. In practice, this allows for specific targeting of these active T-cells by rimiducid which results in a decrease in circulating cell numbers of over 90% in the setting of graft versus host disease. This specificity spares non-alloreactive T-cells and allows for successful reconstitution of the transplanted immune system from these cells.[24753538] Additionally, these non-alloreactive cells retain their sensitivity to rimiducid.

TargetActionsOrganism
USerine/threonine-protein kinase mTOR
ligand
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. DeRose R, Miyamoto T, Inoue T: Manipulating signaling at will: chemically-inducible dimerization (CID) techniques resolve problems in cell biology. Pflugers Arch. 2013 Mar;465(3):409-17. doi: 10.1007/s00424-012-1208-6. Epub 2013 Jan 9. [PubMed:23299847]
  2. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM: An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 1;105(11):4247-54. doi: 10.1182/blood-2004-11-4564. Epub 2005 Feb 22. [PubMed:15728125]
  3. Gargett T, Brown MP: The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014 Oct 28;5:235. doi: 10.3389/fphar.2014.00235. eCollection 2014. [PubMed:25389405]
  4. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK: Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152. [PubMed:22047558]
  5. Definition of rimiducid - NCI Drug Dictionary - National Cancer Institute [Link]
  6. Technology - Bellicum Pharmaceuticals, Inc. [Link]
External Links
PubChem Substance
347909868
ChemSpider
17292138
ChEMBL
CHEMBL269259

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukemia (AML) / Chronic Chronic myelogenous leukemia / Epstein Barr Virus Infections / Epstein-Barr Virus Infections / Familial Hemophagocytic Lymphohistiocytosis / Hemophagocytic Syndrome / Lymphohistiocytosis, Hemophagocytic / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / X-Linked Lymphoproliferative Disease1
1Active Not RecruitingTreatmentHaemoglobinopathies congenital / Inherited Bone Marrow Failure Syndromes / Lymphohistiocytosis, Hemophagocytic / Metabolic Disorders / Primary Immune Deficiency Disorders (PIDD)1
1Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes (MDS) / Neoplasms, Hematologic1
1CompletedTreatmentCastrate Resistant Prostate Cancer (CRPC)1
1CompletedTreatmentCastrate Resistent Prostate Cancer1
1CompletedTreatmentMelanoma / Neuroblastomas / Sarcoma, Osteogenic / Sarcomas1
1Enrolling by InvitationOtherMultiple Myeloma (MM)1
1RecruitingTreatmentBreast Cancer / Metastatic HER2-negative Breast1
1RecruitingTreatmentGenital Neoplasms, Male / Genitourinary tract neoplasm / Metastatic Castration Resistant Prostate Cancer / Neoplasms / Neoplasms by Histologic Type / Neoplasms by Site / Neoplasms of the Prostate / Prostate Cancer / Prostate Neoplasms / Prostatic Diseases / Prostatic Neoplasms / Prostatic Neoplasms, Castration-Resistant1
1RecruitingTreatmentImmune System Diseases / Immunoproliferative Disorders / Lymphatic Diseases / Lymphoma, B-Cell / Malignant Lymphomas1
1RecruitingTreatmentMalignancies, Hematologic1
1RecruitingTreatmentMultiple Myeloma (MM) / Myeloma, Plasma-Cell1
1SuspendedTreatmentAcute Bilineal Leukemia / Acute Lymphoblastic Leukaemia Recurrent / Acute, recurrent Myeloid Leukemia / Chronic, recurrent Lymphocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myelodysplastic/Myeloproliferative Neoplasms / Myeloproliferative Neoplasms / Recurrent Acute Biphenotypic Leukemia / Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Chronic Myelomonocytic Leukemia / Recurrent Myelodysplastic Syndrome1
1WithdrawnTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes (MDS) / Other High-risk Hematological Malignancies1
1WithdrawnTreatmentMalignancies, Hematologic / Neoplasms, Hematologic1
1, 2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukemia (AML) / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aplastic Anemia / Cytopenias / Hemoglobinopathy in Children / Immunologic Deficiency Syndromes / Leukemia, Acute Myeloid (AML), Child / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL) / Osteopetrosis / Primary Immune Deficiency Disorders (PIDD)1
1, 2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Melanoma, Uveal / Myelodysplastic Syndrome1
1, 2Enrolling by InvitationTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aplastic Anemia / Congenital Hypoplastic Anemia / Congenital Immunodeficiency / Cytopenias / Diamond Blackfan Anemia / Haemoglobinopathies congenital / Leukemia, Acute Myeloid (AML), Child / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL) / Sickle Cell Anemia / Thalassaemic disorders1
1, 2RecruitingPreventionGraft Versus Host Disease (GVHD) / Haematological Malignancies1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Immune System Diseases / Immunoproliferative Disorders1
1, 2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / B-lymphoid Malignancies / Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentAdenocarcinoma of the Pancreas / Adenocarcinoma, Prostate / Gastric Adenocarcinoma1
1, 2RecruitingTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentLeukemias / Myeloproliferative Disorders / Plasma Cell Myeloma1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aplastic Anemia / Congenital Hypoplastic Anemia / Congenital Immunodeficiency / Cytopenias / Diamond Blackfan Anemia / Haemoglobinopathies congenital / Leukemia, Acute Myeloid (AML), Child / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / Osteopetrosis / Sickle Cell Anemia / Thalassaemic disorders1
2, 3TerminatedTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
Not AvailableNo Longer AvailableNot AvailableAcute Lymphoblastic Leukaemias (ALL) / Immune System Diseases / Immunoproliferative Disorders1
Not AvailableNo Longer AvailableNot AvailableHurler's Syndrome / Inborn Errors of Metabolism / Inherited Metabolic Disorder / Lysosomal Storage Disorders / Metachromatic Leukodystrophy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000397 mg/mLALOGPS
logP6.88ALOGPS
logP10.06ChemAxon
logS-6.6ALOGPS
pKa (Strongest Acidic)14.34ChemAxon
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area262.18 Å2ChemAxon
Rotatable Bond Count39ChemAxon
Refractivity379.49 m3·mol-1ChemAxon
Polarizability153.98 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Ligand
General Function
Tfiiic-class transcription factor binding
Specific Function
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly...
Gene Name
MTOR
Uniprot ID
P42345
Uniprot Name
Serine/threonine-protein kinase mTOR
Molecular Weight
288889.05 Da

Drug created on October 21, 2007 16:23 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates